Creatine Parkinson trial begins

March 26, 2007

A large-scale national clinical trial has started to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease.

While creatine is not an approved therapy for Parkinson's or any other condition, the potential benefit of creatine in fighting Parkinson's disease was identified by researchers through a new rapid method for screening potential compounds.

The double-blind, placebo-controlled, Phase III study -- one of the largest Parkinson's clinical trials to date -- is being conducted at 51 medical centers in the United States and Canada, involving 1,720 people with early stage Parkinson's.

The National Institutes of Health trial is designed to allow researchers to work with Parkinson's patients over a long period of time, with a goal of finding effective and lasting treatments.

"This study represents the next major step in the quest for a medicine that can slow down the progression of Parkinson's disease," said Dr. John Fang, a Vanderbilt University Medical Center neurologist and one of the study's investigators. "Earlier studies have shown promising results, but without a long-term study, we cannot know for sure."

Copyright 2007 by United Press International

Related Stories

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.